HBM HOLDINGS-B (02142) and Collenbotech (06990) have entered into an exclusive licensing agreement with Windward Bio AG regarding HBM9378/SKB378.

HBM HOLDINGS-B (02142) announced that the company and Corning BioTherapeutics (06990) have entered into an exclusive licensing agreement with Windward Bio AG (Windward Bio) for the joint development of the monoclonal antibody HBM9378/SKB378, targeting thymic stromal lymphopoietin (TSLP). According to the licensing agreement, the company and Corning BioTherapeutics, as licensors, agree to grant Windward Bio global exclusive license to manufacture, develop, use, promote, sell, promise to sell, import, and commercialize HBM9378/SKB378 (now also known as WIN378) in the Greater China region and several countries in Southeast Asia and West Asia. Under the terms of the licensing agreement, the licensors are entitled to receive up to a total of $970 million in upfront and milestone payments, as well as royalties ranging from single to double-digit percentages of net sales. The $45 million upfront payment and recent milestone payments include cash payments and equity in Windward Bio's parent company. If Windward Bio undergoes a change in control or enters into sublicensing agreements with third parties, the licensors are also entitled to receive additional payments from Windward Bio. Payments made by Windward Bio to the licensors under the licensing agreement are to be equally distributed to the company and Corning BioTherapeutics. The company will leverage this opportunity to further strengthen its global collaboration network and maximize the scientific and commercial value of its technology platform. The execution of the licensing agreement will integrate the research and development, production, and commercialization capabilities of the licensors and Windward Bio, providing support for the commercialization of HBM9378/SKB378 and establishing a favorable market position. The implementation of the licensing agreement will also allow the company to launch HBM9378/SKB378 into the global market and maximize its commercial value.